DK2626417T3 - Fremgangsmåder til celleekspansion og anvendelse af derved producerede celler og konditionerede medier til terapi - Google Patents

Fremgangsmåder til celleekspansion og anvendelse af derved producerede celler og konditionerede medier til terapi Download PDF

Info

Publication number
DK2626417T3
DK2626417T3 DK13164303.3T DK13164303T DK2626417T3 DK 2626417 T3 DK2626417 T3 DK 2626417T3 DK 13164303 T DK13164303 T DK 13164303T DK 2626417 T3 DK2626417 T3 DK 2626417T3
Authority
DK
Denmark
Prior art keywords
cells
adherent
cell
medium
culture
Prior art date
Application number
DK13164303.3T
Other languages
English (en)
Inventor
Shai Meretzki
Zami Aberman
Ora Burger
Original Assignee
Pluristem Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38522837&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK2626417(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pluristem Ltd filed Critical Pluristem Ltd
Application granted granted Critical
Publication of DK2626417T3 publication Critical patent/DK2626417T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0668—Mesenchymal stem cells from other natural sources
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/50—Placenta; Placental stem cells; Amniotic fluid; Amnion; Amniotic stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0603—Embryonic cells ; Embryoid bodies
    • C12N5/0605—Cells from extra-embryonic tissues, e.g. placenta, amnion, yolk sac, Wharton's jelly
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0653—Adipocytes; Adipose tissue
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0663—Bone marrow mesenchymal stem cells (BM-MSC)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0667—Adipose-derived stem cells [ADSC]; Adipose stromal stem cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0669—Bone marrow stromal cells; Whole bone marrow
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/122—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells for inducing tolerance or supression of immune responses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2513/00—3D culture
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2531/00—Microcarriers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2533/00—Supports or coatings for cell culture, characterised by material
    • C12N2533/30—Synthetic polymers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Neurosurgery (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)

Claims (11)

1. Adhærente stromaceller af et væv, der er valgt blandt gruppen bestående af placenta- og fedtvæv, til anvendelse ved behandling af (a) en tilstand, der er valgt blandt gruppen bestående af blodtab, anæmi, autoimmune lidelser, arthritis, multipel sklerose, graft-versus-host sygdom (GvHD), autoimmun encephalomyelitis (EAE), systemisk lupus erythematosus (SLE), rheumatoid arthritis, systemisk sklerose, Sjøgrens syndrom, myasthenia gravis (MG), Guillain-Barres syndrom (GBS), Hashimotos thyroiditis (HT), Graves' sygdom, insulinafhængig diabetes mellitus (IDDM) og inflammatorisk tarmsygdom; eller (b) en tilstand, der kan have gavn af facilitering af transplantation af hæmatopoietiske stamceller i et individ, hvor de adhærente stromaceller er opnået fra en tredimensional kultur.
2. Konditioneret medium af adhærente stromaceller, der hidrører fra et væv, der er valgt blandt gruppen bestående af placenta- og fedtvæv, til anvendelse ved behandling af en tilstand, der er valgt blandt gruppen bestående af autoimmune lidelser, arthritis, multipel sklerose, graft versus host sygdom (GvHD), autoimmun encephalomyelitis (EAE), systemisk lupus erythematosus (SLE), rheumatoid arthritis, systemisk sklerose, Sjøgrens syndrom, myasthenia gravis (MG), Guillain-Barres syndrom (GBS), Hashimotos thyroiditis (HT), Graves' sygdom, insulinafhængig diabetes mellitus (IDDM) og inflammatorisk tarmsygdom, hvor de adhærente stromaceller er opnået fra en tredimensional kultur.
3. Celler eller medium til anvendelse ifølge krav 1 eller 2, som endvidere omfatter indgift af stamceller.
4. Celler eller medium til anvendelse ifølge krav 3, hvor stamcellerne • omfatter hæmatopoietiske stamceller, og/eller • indgives samtidigt med nævnte konditionerede medium eller adhærente celler, og/eller • indgives efter indgift af nævnte konditionerede medium eller adhærente celler.
5. Celler eller medium til anvendelse ifølge krav 1, hvor den tredimensionale kultur omfatter en 3D-bioreaktor.
6. Celler eller medium til anvendelse ifølge krav 5, hvor bioreaktoren er valgt blandt gruppen bestående afen stempelstrømningsbioreaktor, en tankbioreaktor med kontinuerlig omrøring og en bioreaktor med stationært leje.
7. Celler eller medium til anvendelse ifølge krav 1, hvor • dyrkningen af cellerne foretages under en kontinuerlig strøm af et kulturmedium, og/eller • den tredimensionale kultur omfatter et adhærent materiale, der er valgt blandt gruppen bestående afen polyester, en polyalkylen, en polyfluorchlorethylen, et polyvinylchlorid, en polystyren, en polysulfon, et celluloseacetat, en glasfiber, en keramisk partikel, en matrigel, en ekstracellulær matrixkomponent, en collagen, en poly-L-mælkesyre og en inert metalfiber, og/eller • dyrkningen foretages i mindst 3 dage, og/eller • dyrkningen foretages, indtil de adhærente celler når mindst 60 % sammenflydning, og/eller • de adhærente celler omfatter et positivt markørekspressionsarray, der er valgt blandt gruppen bestående af CD73, CD90, CD29 og CD105, og/eller • de adhærente celler omfatter et negativt markørekspressionsarray, der er valgt blandt gruppen bestående af CD45, CD80, HLA-DR, CDIIb, CD14, CD19, CD34 og CD79, og/eller • de adhærente celler udskiller et højere niveau af mindst en faktor, der er valgt blandt gruppen bestående af SCF, Flt-3 og IL-6, som er højere end det, der udskilles af adhærente celler fra placenta- eller fedtvæv, der dyrkes i en 2D-kultur, og/eller • de adhærente celler udtrykker et højere niveau af mindst et protein, der er valgt blandt gruppen bestående af H2A histonfamilie (H2AF), aldehyddehydrogenase X (ALDH X), eukaryotisk translationselongeringsfaktor 2 (EEEF2), reticulocalbin 3, EF- hand calciumbindingsdomæne (R.CN2)og calponin 1 basisk glatmuskel (CNN1), end det, der udskilles af adhærente celler fra placenta- eller fedtvæv, der dyrkes i en 2D-kultur, og/eller • de adhærente celler udtrykker et lavere ekspressionsniveau af mindst et protein, der er valgt blandt gruppen bestående af heterogen nuklear ribonucleoprotein HI (Hnrphl), CD44 antigen-isoform 2-præcursor, 3-phosphoadenosin-5-phosphosulfatsynthase-2-isoform a (Papss2) og ribosomalt protein L7a (rpL7a), end det, der udskilles af adhærente celler fra placenta- eller fedtvæv, der dyrkes i en 2D-kultur.
8. Celler eller medium til anvendelse ifølge krav 1, hvor de adhærente celler eller mediet er kendetegnet ved en højere immununosuppressiv aktivitet end den af adhærente celler af placenta- eller fedtvæv, der dyrkes i en 2D-kultur.
9. Celler eller medium til anvendelse ifølge krav 8, hvor den immunosuppressive aktivitet omfatter reduktion af T-celIeproliteration.
10. Celler eller medium til anvendelse ifølge krav 1 eller 2, hvor cellerne omfatter celler, der har en stromastamcellephenotype.
11. Celler eller medium til anvendelse ifølge krav 10, hvor stromastamcellephenotypen omfatter T-cellesuppressionsaktivitet og/eller hæmatopoietisk stamcellestøtteaktivitet.
DK13164303.3T 2006-03-23 2007-03-22 Fremgangsmåder til celleekspansion og anvendelse af derved producerede celler og konditionerede medier til terapi DK2626417T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US78476906P 2006-03-23 2006-03-23
US84708806P 2006-09-26 2006-09-26
EP20110170055 EP2366775B1 (en) 2006-03-23 2007-03-22 Methods for cell expansion and uses of cells and conditioned media produced thereby for therapy

Publications (1)

Publication Number Publication Date
DK2626417T3 true DK2626417T3 (da) 2015-11-02

Family

ID=38522837

Family Applications (2)

Application Number Title Priority Date Filing Date
DK11170055.5T DK2366775T3 (da) 2006-03-23 2007-03-22 Fremgangsmåder til ekspansion af celler og anvendelse af derved opnåede celler og konditionerede medier til terapi
DK13164303.3T DK2626417T3 (da) 2006-03-23 2007-03-22 Fremgangsmåder til celleekspansion og anvendelse af derved producerede celler og konditionerede medier til terapi

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK11170055.5T DK2366775T3 (da) 2006-03-23 2007-03-22 Fremgangsmåder til ekspansion af celler og anvendelse af derved opnåede celler og konditionerede medier til terapi

Country Status (21)

Country Link
US (2) US20110129447A1 (da)
EP (5) EP2626417B1 (da)
JP (3) JP5733894B2 (da)
KR (2) KR101557256B1 (da)
CN (1) CN105296415A (da)
AU (1) AU2007228341B2 (da)
BR (1) BRPI0709349A2 (da)
CA (1) CA2646384C (da)
DK (2) DK2366775T3 (da)
ES (3) ES2572214T3 (da)
HK (5) HK1136846A1 (da)
HR (1) HRP20160538T1 (da)
HU (1) HUE028796T2 (da)
IL (1) IL236213A (da)
MX (1) MX2008012085A (da)
PL (2) PL2366775T3 (da)
PT (3) PT2626417E (da)
RU (1) RU2433177C2 (da)
SG (1) SG170761A1 (da)
SI (1) SI2548951T1 (da)
WO (1) WO2007108003A2 (da)

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9592258B2 (en) 2003-06-27 2017-03-14 DePuy Synthes Products, Inc. Treatment of neurological injury by administration of human umbilical cord tissue-derived cells
AU2004252570C1 (en) 2003-06-27 2012-03-01 Ethicon, Incorporated Soft tissue repair and regeneration using postpartum-derived cells
US8790637B2 (en) 2003-06-27 2014-07-29 DePuy Synthes Products, LLC Repair and regeneration of ocular tissue using postpartum-derived cells
US9572840B2 (en) 2003-06-27 2017-02-21 DePuy Synthes Products, Inc. Regeneration and repair of neural tissue using postpartum-derived cells
CN101374946B (zh) 2005-12-16 2017-07-18 伊西康公司 用于在组织相容性不匹配的移植中抑制有害的免疫反应的组合物和方法
US9125906B2 (en) 2005-12-28 2015-09-08 DePuy Synthes Products, Inc. Treatment of peripheral vascular disease using umbilical cord tissue-derived cells
MX2008012085A (es) * 2006-03-23 2009-01-22 Pluristem Ltd Metodos para expansion de celulas y usos de celulas y medios acondicionados producidos de esta manera para terapia.
US9102915B2 (en) 2006-11-13 2015-08-11 DePuy Synthes Products, Inc. In vitro expansion of postpartum-derived cells using microcarriers
SI2120977T1 (sl) * 2007-02-12 2014-01-31 Anthrogenesis Coroporation Zdravljenje vnetnih bolezni z uporabo placentarnih matičnih celic
JP5162784B2 (ja) * 2007-07-11 2013-03-13 日東電工株式会社 細胞培養基材及びその製造方法並びに細胞培養方法
AU2013267050B2 (en) * 2007-09-19 2016-01-07 Pluristem Ltd. Adherent cells from adipose or placenta tissues and use thereof in therapy
EP3103463B1 (en) * 2007-09-19 2020-01-01 Pluristem Ltd. Adherent cells from adipose or placenta tissues and use thereof in therapy
AU2009252722A1 (en) * 2008-05-27 2009-12-03 Pluristem Ltd. Methods of treating inflammatory colon diseases
CN105766891A (zh) 2008-08-20 2016-07-20 人类起源公司 改进的细胞组合物及制备所述组合物的方法
AU2009288781B2 (en) * 2008-09-02 2015-01-29 Pluri Biotech Ltd Adherent cells from placenta tissue and use thereof in therapy
EP2331957B1 (en) * 2008-09-02 2016-11-02 Pluristem Ltd. Methods of selection of cells for transplantation
US9096827B2 (en) * 2008-09-02 2015-08-04 Pluristem Ltd. Adherent cells from placenta tissue and use thereof in therapy
US10179900B2 (en) 2008-12-19 2019-01-15 DePuy Synthes Products, Inc. Conditioned media and methods of making a conditioned media
BRPI0923068B1 (pt) 2008-12-19 2021-05-25 Advanced Technologies And Regenerative Medicine, Llc Uso de células derivadas de tecido de cordão umbilical para tratar um paciente tendo uma doença, distúrbio ou injúria pulmonar
CN102498204B (zh) 2009-03-26 2015-02-04 德普伊新特斯产品有限责任公司 人脐带组织细胞作为用于阿尔茨海默病的疗法
US9175262B2 (en) 2009-11-30 2015-11-03 Pluristerm Ltd. Adherent cells from placenta and use of same in disease treatment
US9352003B1 (en) 2010-05-14 2016-05-31 Musculoskeletal Transplant Foundation Tissue-derived tissuegenic implants, and methods of fabricating and using same
US8883210B1 (en) 2010-05-14 2014-11-11 Musculoskeletal Transplant Foundation Tissue-derived tissuegenic implants, and methods of fabricating and using same
US10130736B1 (en) 2010-05-14 2018-11-20 Musculoskeletal Transplant Foundation Tissue-derived tissuegenic implants, and methods of fabricating and using same
ES2572211T3 (es) 2010-05-27 2016-05-30 Pluristem Ltd Regeneración de músculo esquelético utilizando células madre mesenquimales
PL2611906T3 (pl) * 2010-08-31 2024-05-27 Gallant Pet, Inc. Ogólnoustrojowe terapie allogenicznymi komórkami macierzystymi do leczenia chorób u kotów i psów
WO2012048275A2 (en) 2010-10-08 2012-04-12 Caridianbct, Inc. Configurable methods and systems of growing and harvesting cells in a hollow fiber bioreactor system
CN103501796A (zh) 2011-03-04 2014-01-08 艾哈迈德·H·阿勒卡塔尼 护肤霜
EP3260533B1 (en) 2011-03-22 2019-09-11 Pluristem Ltd. Methods for treating radiation or chemical injury
IL254464B2 (en) * 2011-04-15 2023-12-01 Pluri Biotech Ltd Methods and systems for harvesting cells
WO2013070734A1 (en) 2011-11-07 2013-05-16 Chaudhry Hina W Methods of cardiac repair
ITTO20111183A1 (it) * 2011-12-21 2013-06-22 Univ Degli Studi Torino Mezzo condizionato ottenuto da cellule staminali mesenchimali placentari e suo uso nel trattamento terapeutico della preeclampsia
SG10201700435XA (en) * 2012-09-04 2017-02-27 Pluristem Ltd Methods for prevention and treatment of preeclampsia
SG11201500816XA (en) 2012-09-06 2015-03-30 Pluristem Ltd Devices and methods for culture of cells
US10351910B2 (en) 2013-02-20 2019-07-16 Pluristem Ltd Gene and protein expression properties of adherent stromal cells cultured in 3D
WO2014141111A1 (en) 2013-03-14 2014-09-18 Pluristem Ltd. Methods for prevention and treatment of graft-versus-host disease
RU2525143C1 (ru) * 2013-03-22 2014-08-10 Федеральное государственное бюджетное учреждение науки Государственный научный центр Российской Федерации-Институт медико-биологических проблем Российской академии наук СПОСОБ ЭКСПАНСИИ МОНОНУКЛЕАРНЫХ КЛЕТОК ПУПОВИННОЙ КРОВИ (пкМНК) ex vivo В ПРИСУТСТВИИ МУЛЬТИПОТЕНТНЫХ СТРОМАЛЬНЫХ МЕЗЕНХИМАЛЬНЫХ КЛЕТОК (ММСК)
RU2539750C2 (ru) * 2013-04-09 2015-01-27 Федеральное государственное бюджетное образовательное учреждение высшего профессионального образования "Московский государственный университет имени М.В. Ломоносова" (МГУ) Способ оценки иммуносупрессивных свойств мезенхимальных стромальных клеток человека
WO2015004609A2 (en) 2013-07-09 2015-01-15 Pluristem Ltd. Adherent cells from placenta and use thereof in treatment of injured tendons
EP3027235A1 (en) 2013-07-30 2016-06-08 Musculoskeletal Transplant Foundation Acellular soft tissue-derived matrices and methods for preparing same
WO2015025059A1 (en) * 2013-08-23 2015-02-26 Fundacion Pública Andaluza Progreso Y Salud Cd105-negative multipotent mesenchymal stromal cells
CN105793411B (zh) 2013-11-16 2018-04-17 泰尔茂比司特公司 生物反应器中的细胞扩增
EP3114206B1 (en) 2014-03-04 2020-07-29 Pluristem Ltd. Systems and methods for growing and harvesting cells
EP3613841B1 (en) 2014-03-25 2022-04-20 Terumo BCT, Inc. Passive replacement of media
US20160090569A1 (en) 2014-09-26 2016-03-31 Terumo Bct, Inc. Scheduled Feed
RU2644650C2 (ru) 2014-12-01 2018-02-13 Общество с ограниченной ответственностью "Т-Хелпер Клеточные Технологии" Материал стволовых клеток и способ его получения
US10258652B2 (en) 2014-12-18 2019-04-16 Pluristem Ltd. Methods and compositions for treating and preventing muscle wasting disorders
US20180015125A1 (en) 2015-03-23 2018-01-18 Pluristem Ltd. Use of adherent stromal cells for enhancing hematopoiesis in a subject in need thereof
CA2986702C (en) 2015-05-21 2023-04-04 David Wang Modified demineralized cortical bone fibers
WO2017004592A1 (en) 2015-07-02 2017-01-05 Terumo Bct, Inc. Cell growth with mechanical stimuli
US10912864B2 (en) 2015-07-24 2021-02-09 Musculoskeletal Transplant Foundation Acellular soft tissue-derived matrices and methods for preparing same
US11052175B2 (en) 2015-08-19 2021-07-06 Musculoskeletal Transplant Foundation Cartilage-derived implants and methods of making and using same
RU2628092C1 (ru) * 2016-02-10 2017-08-14 Федеральное государственное бюджетное учреждение науки Государственный научный центр Российской Федерации - Институт медико-биологических проблем Российской академии наук (ГНЦ РФ - ИМБП РАН) Способ получения МСК-ассоциированных недифференцированных гемопоэтических клеток-предшественников с фенотипов CD34+/CD133+
EP3414320A1 (en) * 2016-02-12 2018-12-19 Cell Care Therapeutics Adipose tissue derived mesenchymal stromal cell conditioned media and methods of making and using the same
IL261146B (en) 2016-02-18 2022-07-01 Pluristem Ltd Methods and compounds for the treatment of cancerous tumors and malignancies
EP3464565A4 (en) 2016-05-25 2020-01-01 Terumo BCT, Inc. CELL EXPANSION
RU2708329C2 (ru) 2016-05-31 2019-12-05 Общество с ограниченной ответственностью "Т-Хелпер Клеточные Технологии" Материал стволовых клеток, композиции и способы применения
US10851347B2 (en) 2016-06-06 2020-12-01 Pluristem Ltd. Altered adherent stromal cells and methods of producing and using same
US11104874B2 (en) 2016-06-07 2021-08-31 Terumo Bct, Inc. Coating a bioreactor
US11685883B2 (en) 2016-06-07 2023-06-27 Terumo Bct, Inc. Methods and systems for coating a cell growth surface
US20200080147A1 (en) * 2017-02-20 2020-03-12 Pluristem Ltd. Methods and compositions for tumor assessment
US11624046B2 (en) 2017-03-31 2023-04-11 Terumo Bct, Inc. Cell expansion
CN110831694A (zh) * 2017-03-31 2020-02-21 细尔琳生物医学公司 生物相容性调整细胞培养基组合物及其用途
JP7393945B2 (ja) 2017-03-31 2023-12-07 テルモ ビーシーティー、インコーポレーテッド 細胞増殖
IL270114B2 (en) 2017-04-24 2024-01-01 Pluri Biotech Ltd Methods and compounds for the treatment of neurological diseases
WO2018199194A1 (ja) * 2017-04-25 2018-11-01 北海道公立大学法人札幌医科大学 間葉系幹細胞の製造方法、間葉系幹細胞の治療効果マーカー及び治療効果判定方法、並びに間葉系幹細胞を含む細胞製剤
IL260253A (en) 2017-07-03 2019-01-31 Pluristem Ltd Methods and compounds for removing adherent cells
WO2019175773A1 (en) 2018-03-12 2019-09-19 Universidade Do Porto Compositions for use in the treatment of musculoskeletal conditions and methods for producing the same leveraging the synergistic activity of two different types of mesenchymal stromal/stem cells
WO2022164788A2 (en) * 2021-01-26 2022-08-04 The Trustees Of Indiana University Pharmaceutical compositions and their methods of use
CN112813002B (zh) * 2021-02-07 2022-11-08 天津科技大学 一株耐热短乳杆菌及其后生素制剂的应用

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154600B (nl) 1971-02-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen.
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
NL154599B (nl) 1970-12-28 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen, alsmede testverpakking.
US3901654A (en) 1971-06-21 1975-08-26 Biological Developments Receptor assays of biologically active compounds employing biologically specific receptors
US3853987A (en) 1971-09-01 1974-12-10 W Dreyer Immunological reagent and radioimmuno assay
US3867517A (en) 1971-12-21 1975-02-18 Abbott Lab Direct radioimmunoassay for antigens and their antibodies
NL171930C (nl) 1972-05-11 1983-06-01 Akzo Nv Werkwijze voor het aantonen en bepalen van haptenen, alsmede testverpakkingen.
US3850578A (en) 1973-03-12 1974-11-26 H Mcconnell Process for assaying for biologically active molecules
US3935074A (en) 1973-12-17 1976-01-27 Syva Company Antibody steric hindrance immunoassay with two antibodies
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4034074A (en) 1974-09-19 1977-07-05 The Board Of Trustees Of Leland Stanford Junior University Universal reagent 2-site immunoradiometric assay using labelled anti (IgG)
US3984533A (en) 1975-11-13 1976-10-05 General Electric Company Electrophoretic method of detecting antigen-antibody reaction
US4098876A (en) 1976-10-26 1978-07-04 Corning Glass Works Reverse sandwich immunoassay
US4879219A (en) 1980-09-19 1989-11-07 General Hospital Corporation Immunoassay utilizing monoclonal high affinity IgM antibodies
US5011771A (en) 1984-04-12 1991-04-30 The General Hospital Corporation Multiepitopic immunometric assay
US4666828A (en) 1984-08-15 1987-05-19 The General Hospital Corporation Test for Huntington's disease
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4801531A (en) 1985-04-17 1989-01-31 Biotechnology Research Partners, Ltd. Apo AI/CIII genomic polymorphisms predictive of atherosclerosis
US5266476A (en) 1985-06-18 1993-11-30 Yeda Research & Development Co., Ltd. Fibrous matrix for in vitro cell cultivation
US5863531A (en) * 1986-04-18 1999-01-26 Advanced Tissue Sciences, Inc. In vitro preparation of tubular tissue structures by stromal cell culture on a three-dimensional framework
US5032508A (en) * 1988-09-08 1991-07-16 Marrow-Tech, Inc. Three-dimensional cell and tissue culture system
US5902741A (en) * 1986-04-18 1999-05-11 Advanced Tissue Sciences, Inc. Three-dimensional cartilage cultures
US5272057A (en) 1988-10-14 1993-12-21 Georgetown University Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase
US5192659A (en) 1989-08-25 1993-03-09 Genetype Ag Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes
US6326198B1 (en) 1990-06-14 2001-12-04 Regents Of The University Of Michigan Methods and compositions for the ex vivo replication of stem cells, for the optimization of hematopoietic progenitor cell cultures, and for increasing the metabolism, GM-CSF secretion and/or IL-6 secretion of human stromal cells
US5486359A (en) 1990-11-16 1996-01-23 Osiris Therapeutics, Inc. Human mesenchymal stem cells
US6010696A (en) 1990-11-16 2000-01-04 Osiris Therapeutics, Inc. Enhancing hematopoietic progenitor cell engraftment using mesenchymal stem cells
US5168085A (en) 1991-05-20 1992-12-01 Corning Incorporated Multi-stage twc system
US5281521A (en) 1992-07-20 1994-01-25 The Trustees Of The University Of Pennsylvania Modified avidin-biotin technique
US5629186A (en) 1994-04-28 1997-05-13 Lockheed Martin Corporation Porous matrix and method of its production
US5736396A (en) 1995-01-24 1998-04-07 Case Western Reserve University Lineage-directed induction of human mesenchymal stem cell differentiation
US6132463A (en) 1995-05-19 2000-10-17 Etex Corporation Cell seeding of ceramic compositions
US5925567A (en) 1995-05-19 1999-07-20 T. Breeders, Inc. Selective expansion of target cell populations
JP3781433B2 (ja) 1995-11-16 2006-05-31 ケース ウエスターン リザーブ ユニバーシティ ヒト間葉幹細胞の試験管内軟骨形成誘導
US6087129A (en) * 1996-01-19 2000-07-11 Betagene, Inc. Recombinant expression of proteins from secretory cell lines
US6335195B1 (en) 1997-01-28 2002-01-01 Maret Corporation Method for promoting hematopoietic and mesenchymal cell proliferation and differentiation
US6291240B1 (en) * 1998-01-29 2001-09-18 Advanced Tissue Sciences, Inc. Cells or tissues with increased protein factors and methods of making and using same
ATE227338T1 (de) 1998-03-18 2002-11-15 Massachusetts Inst Technology Vaskularisierte perfundierte anordnungen für mikrogewebe und mikroorgane
AU4336599A (en) 1998-06-08 1999-12-30 Osiris Therapeutics, Inc. (in vitro) maintenance of hematopoietic stem cells
US6153432A (en) 1999-01-29 2000-11-28 Zen-Bio, Inc Methods for the differentiation of human preadipocytes into adipocytes
DE60043534D1 (de) * 1999-02-04 2010-01-28 Pluristem Ltd VERFAHREN UND VORRICHTUNG ZUR HALTUNG UND EXPANSION VON HEMATOPOIETISCHEN STAMMZELLEN UND/ODER VORLäUFERZELLEN
KR100968164B1 (ko) * 1999-03-10 2010-07-06 더 리전츠 오브 더 유니버시티 오브 캘리포니아 지방 유래 간세포 및 격자
WO2000073421A2 (en) 1999-06-02 2000-12-07 Lifebank Services, L.L.C. Methods of isolation, cryopreservation, and therapeutic use of human amniotic epithelial cells
US6555374B1 (en) 1999-08-19 2003-04-29 Artecel Sciences, Inc. Multiple mesodermal lineage differentiation potentials for adipose tissue-derived stromal cells and uses thereof
AU2001238695B2 (en) 2000-02-26 2005-11-24 Artecel Sciences, Inc. Pleuripotent stem cells generated from adipose tissue-derived stromal cells and uses thereof
ATE360063T1 (de) * 2000-10-12 2007-05-15 Agency Science Tech & Res Nicht störendes, dreidimensionales system für die kultivierung und ernte verankerungsabhängiger zellen
US7311905B2 (en) * 2002-02-13 2007-12-25 Anthrogenesis Corporation Embryonic-like stem cells derived from post-partum mammalian placenta, and uses and methods of treatment using said cells
EP1349918B1 (en) * 2000-12-06 2014-08-06 Anthrogenesis Corporation Method of collecting placental stem cells
ES2444548T3 (es) * 2001-02-14 2014-02-25 Anthrogenesis Corporation Renovación y repoblación de tejidos y órganos cadavéricos descelularizados por células madre
WO2002064755A2 (en) * 2001-02-14 2002-08-22 Anthrogenesis Corporation Post-partum mammalian placenta, its use and placental stem cells therefrom
CA2466880A1 (en) * 2001-11-09 2003-05-15 Artecel Sciences, Inc. Methods and compositions for the use of stromal cells to support embryonic and adult stem cells
JP2003180334A (ja) * 2001-12-17 2003-07-02 Japan Science & Technology Corp 三次元高密度細胞培養用モジュール
US7504099B2 (en) 2001-12-27 2009-03-17 Yissum Research Development Company Of The Hebrew University Of Jerusalem Methods of inducing or enhancing connective tissue repair
US7498171B2 (en) * 2002-04-12 2009-03-03 Anthrogenesis Corporation Modulation of stem and progenitor cell differentiation, assays, and uses thereof
CA2483010A1 (en) * 2002-04-19 2003-10-30 University Of Pittsburgh Of The Commonwealth System Of Higher Education Placental derived stem cells and uses thereof
US20060172304A1 (en) 2003-02-27 2006-08-03 Elaine Fuchs Method for modulating epithelial stem cell lineage
AU2004252570C1 (en) * 2003-06-27 2012-03-01 Ethicon, Incorporated Soft tissue repair and regeneration using postpartum-derived cells
US6924458B2 (en) 2003-07-17 2005-08-02 Great Computer Corp. Auxiliary focusing tool for laser marker
US7790458B2 (en) * 2004-05-14 2010-09-07 Becton, Dickinson And Company Material and methods for the growth of hematopoietic stem cells
DE102004043256B4 (de) * 2004-09-07 2013-09-19 Rheinische Friedrich-Wilhelms-Universität Bonn Skalierbarer Prozess zur Kultivierung undifferenzierter Stammzellen in Suspension
CN103356706B (zh) 2005-03-31 2016-01-20 斯丹姆涅恩有限公司 促进无疤愈合或改善皮肤外观的美容制剂
US20100233130A1 (en) * 2006-02-06 2010-09-16 Pluristem Ltd. Method and Apparatus for Maintenance and Expansion of Hematopoietic Stem Cells From Mononuclear Cells
MX2008012085A (es) * 2006-03-23 2009-01-22 Pluristem Ltd Metodos para expansion de celulas y usos de celulas y medios acondicionados producidos de esta manera para terapia.
EP3260533B1 (en) * 2011-03-22 2019-09-11 Pluristem Ltd. Methods for treating radiation or chemical injury

Also Published As

Publication number Publication date
EP3091071A1 (en) 2016-11-09
AU2007228341A1 (en) 2007-09-27
US20160022738A1 (en) 2016-01-28
RU2433177C2 (ru) 2011-11-10
BRPI0709349A2 (pt) 2011-07-12
PL2548951T3 (pl) 2016-08-31
ES2537641T3 (es) 2015-06-10
EP2366775A1 (en) 2011-09-21
CA2646384A1 (en) 2007-09-27
KR20080110831A (ko) 2008-12-19
HK1160174A1 (en) 2012-08-10
CN105296415A (zh) 2016-02-03
JP2009531059A (ja) 2009-09-03
KR101490449B1 (ko) 2015-02-05
JP5941454B2 (ja) 2016-06-29
KR101557256B1 (ko) 2015-10-02
ES2549528T3 (es) 2015-10-29
EP2366775B1 (en) 2015-04-22
PT2548951E (pt) 2016-06-14
HRP20160538T1 (hr) 2016-07-15
WO2007108003A3 (en) 2009-02-12
EP2010647A4 (en) 2010-05-19
DK2366775T3 (da) 2015-06-15
PL2366775T3 (pl) 2015-08-31
JP5766041B2 (ja) 2015-08-19
PT2366775E (pt) 2015-07-20
HK1187950A1 (en) 2014-04-17
IL236213A (en) 2017-09-28
EP2548951B1 (en) 2016-05-04
CA2646384C (en) 2020-03-24
RU2008141894A (ru) 2010-05-10
AU2007228341B2 (en) 2013-10-17
EP2010647A2 (en) 2009-01-07
JP2014088408A (ja) 2014-05-15
EP3091071B1 (en) 2019-07-03
HK1217513A1 (zh) 2017-01-13
US20110129447A1 (en) 2011-06-02
KR20140136045A (ko) 2014-11-27
HUE028796T2 (en) 2017-01-30
EP2548951A1 (en) 2013-01-23
JP2011219486A (ja) 2011-11-04
EP2626417B1 (en) 2015-09-02
MX2008012085A (es) 2009-01-22
SI2548951T1 (sl) 2016-07-29
ES2572214T3 (es) 2016-05-30
PT2626417E (pt) 2015-11-16
JP5733894B2 (ja) 2015-06-10
EP2626417A1 (en) 2013-08-14
HK1136846A1 (en) 2010-07-09
HK1177759A1 (zh) 2013-08-30
WO2007108003A2 (en) 2007-09-27
SG170761A1 (en) 2011-05-30

Similar Documents

Publication Publication Date Title
DK2626417T3 (da) Fremgangsmåder til celleekspansion og anvendelse af derved producerede celler og konditionerede medier til terapi
US20200306319A1 (en) Methods for treating radiation or chemical injury
US20110171182A1 (en) Methods for cell expansion and uses of cells and conditioned media produced thereby for therapy
US20110293583A1 (en) Methods for cell expansion and uses of cells and conditioned media produced thereby for therapy
US20140017209A1 (en) Methods for treating radiation or chemical injury
US20210113627A1 (en) Adherent stromal cells derived from placentas of multiple donors and uses thereof